Clinical trial register · Spain

Clinical Trials in Madrid, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Madrid

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Recruiting

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed

AstraZeneca

Phase 1/2

152

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Valencia

2025-11-24

Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310Parkinson's Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 3

900

Elche, Sant Cugat del Vallès, Donostia / San Sebastian, A Coruña, Alcorcón, Pozuelo de Alarcón, Barcelona, Madrid

2025-11-24

Recruiting

A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

NCT07227857Epileptic Encephalopathy

Institut de Recherches Internationales Servier

Phase 1/2

Esplugues de Llobregat, Madrid

2025-11-24

Recruiting

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778Symptomatic Venous Thromboembolism (VTE)

DrugsCenvacibart·Acetylsalicylic acid

Regeneron Pharmaceuticals

Phase 3

2,000

Vitoria-Gasteiz, Marbella, Pamplona, Barcelona, Madrid, Valencia

2025-11-24

Recruiting

Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th

NCT07655115Autism Spectrum Disorders

Hospital General Universitario Gregorio Marañon

Phase 3

103

Barcelona, Madrid, Salamanca, Zamora

2025-11-20

Recruiting

Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice

NCT07252765Type 2 Diabetes Mellitus (T2DM), Malnutrition, Malnourishment, Drug-Induced Diabetes

Outcomes'10

Observational

334

Santander, Huelva, Las Palmas de Gran Canaria, Madrid, Málaga, Oviedo, Seville, Valencia

2025-11-20

Active, closed

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)

DrugVX-407

Vertex Pharmaceuticals Incorporated

Phase 2

Barcelona, Madrid

2025-11-19

Recruiting

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum

Crinetics Pharmaceuticals Inc.

Phase 3

141

Barcelona, Madrid, Málaga, Seville, Valencia

2025-11-19

Active, closed

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

NCT07211685Alport Syndrome

Bayer

Phase 2

Alcázar de San Juan, Barcelona, Madrid, Seville

2025-11-19

Recruiting

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

111

Esplugues de Llobregat, Barcelona, Córdoba, Madrid, Málaga, Seville

2025-11-19

Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832Metastatic Colorectal Cancer (CRC)

DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin

Summit Therapeutics

Phase 3

600

A Coruña, Barcelona, Córdoba, Granada, Madrid, Málaga, Palma de Mallorca, Santander

2025-11-18

Recruiting

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

NCT06948448Colorectal Cancer

DrugsONO-4578·Leucovorin·Opdivo·Adrucil

Ono Pharmaceutical Co., Ltd.

Phase 2

144

Badalona, Barcelona, Córdoba, Madrid, Seville, Málaga, Valencia

2025-11-18

Recruiting

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842Advanced Solid Cancers

BioNTech SE

Phase 1/2

245

Barcelona, Logroño, Madrid, Pozuelo de Alarcón

2025-11-18

Recruiting

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

NCT06887803Myelofibrosis (MF)

DrugRoginolisib

iOnctura

Phase 1/2

Barcelona, Madrid, Salamanca

2025-11-17

Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420Palmoplantar Pustulosis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

320

Alicante, Badalona, Granada, Madrid, Manises, Málaga, Santiago de Compostela, Valencia

2025-11-14

Recruiting

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

NCT06804811NonSegmental Vitiligo

DrugRuxolitinib

Incyte Corporation

Phase 3

250

Alcorcón, Badalona, Barcelona, Esplugues de Llobregat, Madrid, Zaragoza

2025-11-13

Active, closed

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

NCT07074886Multiple Sclerosis

Hoffmann-La Roche

Phase 2

193

Las Palmas de Gran Canaria, EL Palmar (EL Palmar), Albacete, Alicante, Barcelona, Madrid, Seville

2025-11-13

Active, closed

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

NCT07228390Hidradenitis Suppurativa

DrugRitlecitinib

Pfizer

Phase 2

128

Manises, Cadiz, Granada, Madrid, Pontevedra

2025-11-13

Active, closed

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

NCT07036523Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim

Phase 2

Barcelona, L Hospitalet Del Llobregat, Madrid, Seville

2025-11-13

Active, closed

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,060

Santander, Barcelona, Madrid, Seville, Valencia

2025-11-12

Recruiting

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07023627Ovarian Cancer

DrugINCB123667

Incyte Corporation

Phase 2

160

Barcelona, Córdoba, Girona, Madrid, Murcia, Valencia

2025-11-12

Recruiting

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101Ulcerative Colitis

DrugsZotemtegrast·Mirikizumab

Eli Lilly and Company

Phase 2

252

Barcelona, Fuenlabrada, Gijón, Madrid

2025-11-10

Recruiting

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration

ADARx Pharmaceuticals, Inc.

Phase 2

240

Barcelona, Madrid, Valencia

2025-11-10

Active, closed

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820Pulmonary Hypertension

Pfizer

Phase 2

Madrid

2025-11-10

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 3

670

A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga, Palma de Mallorca

2025-11-07

Recruiting

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization

DrugAZD0292

AstraZeneca

Phase 2

435

Barcelona, Benalmádena, Madrid, Mérida, Patraix, Valencia

2025-11-06

Recruiting

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

NCT07206225Non-muscle Invasive Bladder Cancer

DrugSasanlimab

Pfizer

Phase 1

294

Madrid

2025-11-06

Recruiting

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

NCT07170917Hidradenitis Suppurativa

DrugBrivekimig

Sanofi

Phase 2

208

Santiago de Compostela, Las Palmas de Gran Canaria, Manises, Cadiz, Granada, Madrid

2025-11-06

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080Non-Small Cell Lung Cancer

DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

500

Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia, Zaragoza

2025-11-05

Recruiting

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065Neovascular Age-related Macular Degeneration

DrugSurabgene Lomparvovec

AbbVie

Phase 3

561

Córdoba, Donostia / San Sebastian, Majadahonda, Asturias, Seville, Barcelona, Madrid, Valencia

2025-11-05

Recruiting

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

NCT07064122Haematologic Neoplasms

AstraZeneca

Phase 1

Barcelona, Madrid, Pamplona, Salamanca, Valencia

2025-11-03

Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Ribociclib·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

1,000

Alicante, Barcelona, Granada, León, Lleida, Madrid, Murcia, Seville

2025-11-03

Recruiting

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

NCT07203001Still´s Disease

DrugArumakimig

Novartis Pharmaceuticals

Phase 2

Esplugues, Madrid, Valencia

2025-11-03

Recruiting

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

NCT06243731Cytomegalovirus (CMV), Kidney Disease, Kidney Failure

Takeda

Observational

L'Hospitalet de Llobregat, Barakaldo, Barcelona, Córdoba, Madrid, Málaga, Seville

2025-11-03

Active, closed

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

NCT07287644Hidradenitis Suppurativa (HS)

DrugBFB759

Bluefin Biomedicine, Inc.

Phase 2/3

210

Granada, Granollers, Las Palmas de Gran Canaria, Madrid, Pontevedra, Valencia

2025-11-03

Recruiting

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

NCT07108283Nonsegmental Vitiligo

DrugZasocitinib

Takeda

Phase 2

200

Las Palmas de Gran Canaria, Córdoba, Madrid, Valencia

2025-11-03

Recruiting

Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.

NCT07537517Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension (PH), Heart Failure

Hospital General Universitario Gregorio Marañon

Observational

150

Madrid

2025-11-01

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Zaragoza

2025-10-31

Recruiting

A Study With CIT-013 in HS Patients

NCT06993233Hidradenitis Suppurativa (HS)

DrugsCIT-013 medium·CIT-013

Citryll BV

Phase 2

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2025-10-31

Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

NCT07173751Breast Neoplasms

DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin

BioNTech SE

Phase 3

558

Badajoz, Barcelona, Córdoba, Madrid, Murcia, Pamplona, Sabadell, Valencia

2025-10-30

Recruiting

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

NCT07201051Bronchiectasis

DrugGSK3862995B

GlaxoSmithKline

Phase 2

363

Barcelona, Lleida, Madrid, MErida Badajoz, Oviedo, Valencia

2025-10-30

Recruiting

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

NCT07123155Pompe Disease

Shionogi

Phase 2

Madrid, Valencia

2025-10-30

Not yet open

Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus.

NCT07203664Evaluate the Effectiveness of CMV Prevention Strategies in Kidney Transplant Recipients

Hospital Universitario La Paz

Phase 4

Madrid

2025-10-30

Recruiting

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822Breast Cancer

DrugDato-DXd

AstraZeneca

Phase 3

100

A Coruña, Barcelona, Granada, Madrid, Seville, Valencia

2025-10-30

Recruiting

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)

DrugAvacincaptad Pegol

ONL Therapeutics

Phase 2

324

Barcelona, Bilbao, Córdoba, Madrid, Seville, Valencia, Zaragoza

2025-10-28

Recruiting

PKB171 Against Placebo in Couples With Mild Male Factor Infertility

NCT07669584Infertility Due to Azoospermia

Prokrea BCN, S.L.

Phase 2/3

732

Pamplona, Barcelona, Madrid, Seville

2025-10-28

Recruiting

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

NCT07377045Pancreatic Adenocarcinoma Metastatic

DrugsOMTX705·Nab-paclitaxel·Tislelizumab·Gemcitabine

Oncomatryx Biopharma S.L.

Phase 1

Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Madrid, Pamplona, Santiago de Compostela

2025-10-28

By invitation

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure

Praxis Precision Medicines

Phase 3

700

Barcelona, Madrid, Málaga, Terrassa, Valencia

2025-10-27

Recruiting

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT06405087Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

Ferrol, Madrid, Seville, Valencia

2025-10-27

Recruiting

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT07007962Immune Thrombocytopenia

DrugRilzabrutinib

Sanofi

Phase 3

Barcelona, Burgos, Madrid, Murcia, San Cristóbal de La Laguna, Seville

2025-10-24

Recruiting

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 3

600

Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, Madrid, Málaga, Seville

2025-10-24

Recruiting

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

NCT06899126Non-small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

686

A Coruña, Barcelona, Burgos, Castellion, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga

2025-10-24

Recruiting

Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions

NCT06736899Coronary Artery Disease, Coronary Disease

Fundación EPIC

Not applicable

200

Alicante, Barcelona, Córdoba, Fuencarral-El Pardo, Lugo, Madrid, Salamanca, Seville

2025-10-23

Recruiting

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

NCT07220564Haemophilia A

Novo Nordisk A/S

Phase 1

Barcelona, Madrid, Málaga, Salamanca, Valencia

2025-10-23

Active, closed

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121Pancreatic Ductal Adenocarcinoma

DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

470

Barcelona, Madrid, Seville, Zaragoza

2025-10-23

Recruiting

Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

NCT07168434IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms

DrugSaccharomyces Boulardii

Biocodex

Phase 3

406

Barcelona, León, Madrid, Marbella, Málaga, Oviedo

2025-10-22

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Barcelona, Castellon, Granada, Madrid, Málaga, San Sebastián de los Reyes, Santiago de Compostela, Toledo

2025-10-22

Recruiting

Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma

NCT07251413Cutaneous Basal Cell Carcinoma

DrugsImiquimod·Cemiplimab

Instituto Oncológico Dr Rosell

Phase 1/2

Barcelona, Madrid, Zaragoza

2025-10-22

Recruiting

A Study of ZW251 in Participants With Advanced Solid Tumors

NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor

Zymeworks BC Inc.

Phase 1

140

Barcelona, Logroño, Madrid, Málaga, Pamplona

2025-10-21

Recruiting

A Study of JNT-517 in Participants With Phenylketonuria (PKU)

NCT06971731Phenylketonuria

DrugRepinatrabit

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

120

Madrid, Santiago de Compostela

2025-10-20

Recruiting

Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

NCT07407465Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma

DrugsTrastuzumab deruxtecan·Capecitabine·Bevacizumab

Gruppo Oncologico del Nord-Ovest

Phase 2

Barcelona, Granada, Madrid, Santiago de Compostela, Valencia

2025-10-20

Recruiting

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura

DrugEfgartigimod

argenx

Phase 2/3

Barcelona, Esplugues de Llobregat, Madrid

2025-10-20

Recruiting

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT07213609Neoplasms, Colorectal, Neoplasms

GlaxoSmithKline

Phase 1/2

Barcelona, Madrid

2025-10-20

Recruiting

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy

NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Stemline Therapeutics, Inc.

Observational

140

Albacete, Alicante, Badalona, Burgos, Cáceres, Córdoba, Madrid, Oviedo

2025-10-17

Recruiting

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

NCT07266805Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 3

Madrid

2025-10-16

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

A Coruña, Badalona, Barcelona, Ferrol, Huelva, Madrid, Palma, Pontevedra

2025-10-15

Recruiting

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

NCT07214727Alzheimer's Disease

Alnylam Pharmaceuticals

Phase 1

Barcelona, Madrid, Sant Cugat del Vallès

2025-10-15

Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

NCT07160725Solid Tumours

DrugPumitamig

Bristol-Myers Squibb

Phase 1/2

540

Málaga, Badalona, Barcelona, Pamplona, Madrid

2025-10-15

Recruiting

Changes in Soft Tissue Thickness Following Multiple Coronally Advanced Tunnel (MCAT) vs Vestibular Incision Subperiosteal Tunnel Access (VISTA)

NCT07200258Gingival Recession

Universidad Complutense de Madrid

Not applicable

Madrid

2025-10-15

Recruiting

A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.

NCT05585476Female Urogenital Diseases, Breast Cancer Female

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Not applicable

195

Madrid

2025-10-15

Recruiting

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer

DrugLuxdegalutamide

Novartis Pharmaceuticals

Phase 1/2

188

Santiago Compostela, L'Hospitalet de Llobregat, Madrid

2025-10-15

Recruiting

TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

NCT07284277Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma

Clinica Universidad de Navarra, Universidad de Navarra

Phase 1/2

Pamplona, Barakaldo, Galdakao, Madrid, Vitoria-Gasteiz

2025-10-14

Recruiting

A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

NCT07231458Advanced Solid Tumors

DrugPembrolizumab

Abalos Therapeutics GmbH

Phase 1

Barcelona, Madrid

2025-10-14

Active, closed

Equine Therapy Programme on Stress, Autonomy and Balance in School-age Children With Intellectual Disabilities

NCT07497035Intellectual Disability

Universidad Pontificia Comillas

Not applicable

Madrid

2025-10-10

Recruiting

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2

140

Esplugues, A Coruña, Barcelona, Madrid

2025-10-09

Recruiting

Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis

NCT07465848Lung Cancer (Diagnosis), Health Adult Subjects, Patient

Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)

Not applicable

1,200

Elche, Barcelona, Santander, Madrid, Oviedo, Toledo, Valencia

2025-10-08

Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248Non-small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

675

Badalona, Barcelona, A Coruña, Majadahonda, Valencia, Madrid, Seville

2025-10-08

Recruiting

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsVisugromab·Visugromab RDE·Opdivo·Docetaxel

CatalYm GmbH

Phase 2

131

Jaén, Málaga, Seville, Barcelona, Santiago de Compostela, Girona, Logroño, Madrid

2025-10-07

Recruiting

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

NCT07100106Breast Cancer

DrugsRGT-419B·Giredestrant·Abemaciclib

Genentech, Inc.

Phase 1/2

285

Barcelona, Madrid, Valencia

2025-10-07

Recruiting

Validity of an Open-access Handedness Recognition Task in Stroke Patients

NCT07497464Stroke

Alfredo Lerín Calvo

Observational

Madrid

2025-10-07

Recruiting

A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

NCT07161258Relapsing Multiple Sclerosis

DrugFenebrutinib

Hoffmann-La Roche

Phase 2

Madrid, Seville

2025-10-06

Not yet open

AI-based Progression and Medication Response Prediction Study in Parkinson's Disease

NCT07189468PARKINSON DISEASE (Disorder)

University Hospital, Toulouse

Observational

100

Madrid

2025-10-06

Recruiting

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

NCT07023614Non-obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals, Inc.

Phase 2

165

Barcelona, A Coruña, Madrid, Vigo, Seville, El Palmar, Palma de Mallorca, Salamanca

2025-10-06

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Barcelona, Gijón, Girona, Madrid, Santiago de Compostela, Seville, Valencia

2025-10-03

Recruiting

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

NCT07102628Acute Coronary Syndrome

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

300

Santiago Compostela, Huelva, El Palmar, Las Palmas GC, Madrid, Salamanca, Seville, Valencia

2025-10-03

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Barcelona, Madrid, Oviedo, Málaga

2025-10-03

Recruiting

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857Multiple Myeloma

DrugsCilta-cel·Fludarabine·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Seville

2025-10-03

Recruiting

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

NCT07389265Metastatic Colorectal Cancer (mCRC)

DrugsFOLFOX (Folinic acid·Erbitux·Folfox·Fluorouracil

University of Campania Luigi Vanvitelli

Phase 3

480

Barcelona, Cartagena, Córdoba, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2025-10-01

Recruiting

Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication

NCT07255378Septic Shock

Jamil Cedeño Mora

Observational

1,200

Terrassa, Getafe, Madrid, Majadahonda, Móstoles, Valencia, Zaragoza

2025-10-01

Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161Metastatic Prostate Cancer

DrugPalacaparib

AstraZeneca

Phase 1/2

283

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Valencia

2025-10-01

Recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT05745714Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsRuxolitinib·Cytarabine·Venetoclax·Dexamethasone

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Barcelona, Madrid, Valencia

2025-10-01

Not yet open

Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer

NCT07013851MMRd/MSI-H Stage II-III Endometrial Cancer

DrugDostarlimab

Grupo Español de Investigación en Cáncer de Ovario

Phase 2

Madrid

2025-10-01

Recruiting

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

882

Barcelona, Ferrol, Galdakao, Gijón, Girona, Madrid, Santiago de Compostela, Seville

2025-10-01

Recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT05751044Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsDasatinib·Cytarabine·Venetoclax·Dexamethasone

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Barcelona, Madrid, Valencia

2025-10-01

Recruiting

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

NCT07175038Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease

AllRock Bio, Inc.

Phase 2

Madrid, Toledo

2025-10-01

Recruiting

#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.

NCT06900829HIV Infection, HIV, Stigma, Education

Casper Rokx

Not applicable

5,200

Madrid

2025-10-01

By invitation

A Long-Term Study of Navenibart in Participants With Hereditary Angioedema

NCT07204938Hereditary Angioedema (HAE)

DrugNavenibart

Astria Therapeutics, Inc.

Phase 3

145

Madrid, Valencia

2025-10-01

Recruiting

Accuracy of Metal Sleeve-Free Fully Guided Implant Surgery

NCT07364006Edentulism

Universidad Complutense de Madrid

Not applicable

Madrid

2025-10-01

Recruiting

LONGITUDINAL FOLLOW-UP STUDY TO DETERMINE THE PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED PATIENTS

NCT07167771Periodontal Diseases

Universidad Complutense de Madrid

Observational

100

Madrid

2025-10-01

Recruiting

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931Crohn's Disease

DrugDuvakitug

Sanofi

Phase 3

980

Ourense, Gijón, Huelva, Madrid

2025-10-01

Recruiting

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

NCT07022483Endometrial Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

710

A Coruña, El Palmar, Madrid, Palma de Mallorca

2025-09-30

Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762Urothelial Cancer

DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

470

Barcelona, Santander, Madrid, Valencia, Badajoz, Córdoba, Seville

2025-09-30

Not yet open

"A Privacy-protecting Environment for Child Transplants Health Related and Genomic Data Integration in the European Reference Network"

NCT07194057Transplant Complication, Kidney Transplant, Liver Transplant

Instituto de Investigación Hospital Universitario La Paz

Observational

200

Madrid

2025-09-30

Recruiting

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

NCT07192614Prostate Cancer

AstraZeneca

Phase 1/2

Barcelona, L'Hospitalet de Llobregat, Madrid

2025-09-30

Recruiting

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

NCT07197866Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

200

Barcelona, Madrid, Pamplona, Seville, Valencia

2025-09-30

Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma

NCT07285590Mantle Cell Lymphoma (MCL)

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, El Palmar, Marbella, Pamplona, Salamanca

2025-09-30

Recruiting

TLN-372 in Advanced KRAS Mutant Solid Tumors

NCT07204340KRAS Mutant Solid Tumors

DrugsCetuximab·Pembrolizumab

Treeline Biosciences, Inc.

Phase 1

270

Barcelona, Madrid

2025-09-29

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

A Coruña, Badalona, Barcelona, Madrid, Badajoz, Granada, Palma, Seville

2025-09-29

Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

1,000

Barcelona, Madrid, Vigo, Valencia

2025-09-28

Recruiting

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor

Drug177Lu-edotreotide

ITM Solucin GmbH

Phase 1

Barcelona, Madrid

2025-09-26

Recruiting

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

NCT07190196Immunoglobulin G4 Related Disease

DrugRilzabrutinib

Sanofi

Phase 3

124

Barcelona, Madrid

2025-09-26

Recruiting

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

NCT07007312Acute Myeloid Leukemia (AML)

DrugsZiftomenib·Venclyxto·Ara-C·Daunorubicin

Kura Oncology, Inc.

Phase 3

1,300

Seville, Zaragoza, Burgos, Salamanca, Albacete, Madrid, Oviedo, Valencia

2025-09-26

Recruiting

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)

NCT07290257Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis

DrugMaralixibat

Mirum Pharmaceuticals, Inc.

Phase 4

230

Barcelona, Madrid

2025-09-25

Recruiting

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

NCT07102381HER2-positive Breast Cancer, Breast Cancer

DrugsZanidatamab·Pertuzumab·Trastuzumab·Docetaxel

Jazz Pharmaceuticals

Phase 2

125

Granada, Vigo, Barcelona, Madrid

2025-09-24

Recruiting

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

NCT07109726Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma

DrugFulvestrant

Terremoto Biosciences Inc.

Phase 1/2

205

Madrid

2025-09-23

Recruiting

A Study of PHN-012 in Patients With Advanced Solid Tumors

NCT07127874Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer

Pheon Therapeutics

Phase 1

165

Barcelona, Madrid, Valencia

2025-09-23

Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520Non-small Cell Lung Cancer

DrugsBNT326·Pumitamig

BioNTech SE

Phase 1/2

880

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2025-09-22

Recruiting

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967Plaque Psoriasis

DrugsUstekinumab·Deucravacitinib

Bristol-Myers Squibb

Phase 3

3,040

Badalona, Barcelona, Las Palmas de Gran Canaria, Alcorcón, Málaga, Salamanca, Seville, Madrid

2025-09-22

Recruiting

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

NCT07053423Chronic Obstructive Pulmonary Disease

DrugDupilumab

Sanofi

Phase 4

218

Santander, Barcelona, Pozuelo de Alarcón, Oviedo, Madrid

2025-09-22

Recruiting

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive

DrugGilteritinib

Astellas Pharma Global Development, Inc.

Phase 1

Barcelona, Madrid, Málaga

2025-09-22

Recruiting

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT07157787Primary Membranous Nephropathy

Alexion Pharmaceuticals, Inc.

Phase 2

Barcelona, Madrid, Seville, Toledo

2025-09-19

Active, closed

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,101

Sant Cugat del Vallès, Terrassa, Donostia / San Sebastian, Lleida, Pozuelo de Alarcón, Barcelona, Córdoba, Madrid

2025-09-17

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Zaragoza, Badalona, Santander, Barcelona, Madrid

2025-09-17

Recruiting

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

NCT07176689Desmoid Tumor, Aggressive Fibromatosis

DrugNirogacestat

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 4

Barcelona, Madrid, Valencia, Zaragoza

2025-09-17

Recruiting

iFD-SuRvivE funCtiONal effiCacy and bIologicaL corrElates (RECONCILE Study)

NCT05655390Suicide, Attempted, Functioning, Psychosocial, Cognition, Neuroimaging

Iria Grande

Not applicable

120

Barcelona, Madrid

2025-09-16

Not yet open

Effect of CPAP Versus APAP in Patients With Obesity Undergoing Bariatric Surgery Protocol

NCT07001215Sleep Apnea, Obstructive, Bariatric Surgery, Obesity, Treatment Adherence and Compliance

Hospital Universitario Ramon y Cajal

Not applicable

104

Madrid

2025-09-15

Recruiting

Long Term Effect of Brain Stimulation in PPA

NCT07158216Primary Progressive Aphasia(PPA)

Hospital San Carlos, Madrid

Not applicable

Madrid

2025-09-15

Recruiting

Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)

NCT07205874Primary Biliary Cholangitis (PBC)

Hospital Universitario La Paz

Observational

Madrid

2025-09-15

Not yet open

Safety, Usability, and Effectiveness of a Gait Exoskeleton for Children and Adolescents With Neurodevelopmental Disorders.

NCT07159360Neuromuscular Disorders, Neurodevelopmental Disorders

MarsiBionics

Not applicable

Madrid

2025-09-15

Active, closed

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

NCT06992609Small Cell Lung Carcinoma

DrugDurvalumab

AstraZeneca

Phase 3

A Coruña, Badajoz, Barakaldo, Barcelona, Madrid, Málaga, Oviedo, Santander

2025-09-15

Not yet open

Effectiveness of Immersive Virtual Reality Combined With Occupational Therapy in Reducing Fall Risk and Frailty Among Older Adults

NCT07060677Frailty Syndrome, Older Adults, Balance, Fall Prevention in Healthy Aging

Universidad Rey Juan Carlos

Not applicable

Alcorcón, Madrid

2025-09-15

Recruiting

Using Advanced CT Scans and Blood Markers to Better Understand Heart Damage and Recovery After a Heart Attack

NCT07268391Acute Myocardial Infarction (AMI)

Instituto de Investigación Biomédica de Salamanca

Not applicable

Madrid, Salamanca, Valencia

2025-09-15

Not yet open

A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice

NCT07004439Gastroesophageal Reflux Disease

Implantica CE Reflux Ltd.

Not applicable

500

Getafe, Alcázar de San Juan, Madrid

2025-09-15

Active, closed

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

413

Barcelona, Bilbao, Córdoba, Huelva, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville

2025-09-13

By invitation

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.

NCT06549400Myotonic Dystrophy

DrugMexiletine

Lupin Ltd.

Phase 3

176

Madrid

2025-09-12

Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868Breast Neoplasms

DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

600

A Coruña, Elche, Barcelona, Hospitalet, Donostia / San Sebastian, Madrid, Málaga, Valencia

2025-09-11

Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965Non-Muscle Invasive Bladder Neoplasms

DrugsErdafitinib·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

220

A Coruña, Barcelona, Cadiz, Castellon, Ferrol, Jerez de la Frontera, Madrid, Málaga

2025-09-10

Recruiting

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

NCT07054190Breast Cancer

DrugsGiredestrant·Inavolisib·Ribociclib·Letrozole

Hoffmann-La Roche

Phase 2

120

Barcelona, Madrid, Salamanca, Seville, Valencia

2025-09-09

Recruiting

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

NCT06855771Carcinoma, Non-Small-Cell Lung

DrugsNavlimetostat·Iza-bren

Bristol-Myers Squibb

Phase 2

182

Barcelona, Hospitalet, Madrid, Málaga, Seville, Valencia

2025-09-09

Recruiting

Early Double Sequential Defibrillation in Out of Hospital Cardiac Arrest

NCT07174986Out of Hospital Cardiac Arrest, Ventricular Fibrillation, Defibrillation, CPR

Gabriel Riva

Phase 2/3

916

Málaga, Bilbao, Barcelona, Madrid

2025-09-08

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Santander, Seville

2025-09-08

Not yet open

Evaluation of Functional and Biochemical Effectiveness of a Strength Training Protocol in Parkinson's Disease

NCT07095400Parkinson Disease

Universidad Villanueva

Not applicable

Madrid

2025-09-07

Recruiting

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

NCT07029737Mantle-cell Lymphoma

DrugsLisaftoclax·Acalabrutinib

AstraZeneca

Phase 2

A Coruña, Alcorcón, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Gijón, Madrid

2025-09-05

Recruiting

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsTacabrutideg·Pirtobrutinib

BeOne Medicines

Phase 3

500

Badalona, Burgos, Las Palmas de Gran Canaria, Madrid, Majadahonda, Palma de Mallorca, Seville

2025-09-04

Recruiting

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

NCT07115745Refractory Autoimmune Diseases

DrugsTocilizumab·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

125

Barcelona, Madrid

2025-09-04

Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443Metastatic Castration-resistant Prostatic Neoplasms

DrugsJNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 3

1,203

Barcelona, Jerez de la Frontera, Madrid, Málaga

2025-09-02

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289Colorectal Cancer

DrugTelisotuzumab Adizutecan

AbbVie

Phase 2

140

Seville, Madrid, Salamanca

2025-09-02

Recruiting

Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)

NCT07028827Myopia

DrugAtropine eye

Ocus Innovation Ireland Limited

Phase 3

234

Barcelona, Cadiz, Madrid

2025-09-01

Recruiting

Efficacy of Non-ablative Radiofrequency Combined With Pelvic Floor Muscle Training for Genitourinary Syndrome of Menopause in Breast Cancer Survivors (RF-SGM)

NCT07034976Genitourinary Syndrome of Menopause (GSM), Breast Cancer

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Not applicable

Madrid

2025-09-01

Recruiting

Pain Evaluation Across Robotic and Laparoscopic Surgery for Colorectal Procedures

NCT07431892Minimally Invasive Surgical Procedures, Colon Cancer Patients

Hospital Central de la Defensa Gómez Ulla

Observational

Madrid

2025-09-01

Recruiting

Comparison of Autologous Tooth and Bovine Xenograft in Periodontal Healing After Mandibular Third Molar Extraction

NCT07824518Periodontal Defects After Third Molar Extraction, Periodontal Disease

Universidad Complutense de Madrid

Not applicable

Madrid

2025-09-01

Not yet open

Low Powered Colorectal Anastomosis After Rectal Excision (OASIS)

NCT07146334Rectal Cancer, Surgery Indication

Bordeaux Colorectal Institute

Observational

400

Madrid, Vigo

2025-09

Not yet open

Relieving Carb Counting Via Flexible-userinteraction Multiple-input Control Architectures

NCT07031492T1DM - Type 1 Diabetes Mellitus

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Not applicable

Madrid

2025-09

Not yet open

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

NCT07124884Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer

Federation Francophone de Cancerologie Digestive

Phase 2

300

Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Oviedo, Pamplona, Salamanca, San Carlos

2025-08-31

Recruiting

TRIMODAL PREHABILITATION IN GASTROINTESTINAL CANCER

NCT07281248Digestive Neoplasms

Puerta de Hierro University Hospital

Not applicable

Madrid

2025-08-28

Recruiting

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2

ADARx Pharmaceuticals, Inc.

Phase 3

Barcelona, Madrid

2025-08-28

Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)

ADARx Pharmaceuticals, Inc.

Phase 2

Barcelona, Madrid, Seville

2025-08-28

Recruiting

Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors

NCT07128303Advanced Solid Tumor

DrugsPemetrexed·Carboplatin·Pembrolizumab

Gilead Sciences

Phase 1

476

Barcelona, Madrid

2025-08-28

Recruiting

Medical Device for Sustained Remission in Rheumatoid Arthritis Treated With Biological Therapy

NCT07678112Rheumatoid Arthritis (RA)

Francisco J. Blanco

Not applicable

184

A Coruña, Alava, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna

2025-08-28

Recruiting

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

NCT07200908Chronic Hepatitis D Infection

DrugBulevirtide

Mirum Pharmaceuticals, Inc.

Phase 3

172

Almería, Barcelona, Madrid, Málaga, Santander, Vigo

2025-08-27

Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma

Alentis Therapeutics AG

Phase 1/2

180

Barcelona, Córdoba, El Palmar, Madrid, Seville, Tarragona, Valencia

2025-08-26

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

NCT06925321Invasive Mold Infections

DrugFosmanogepix

Basilea Pharmaceutica

Phase 3

234

Seville, Barcelona, Barakaldo, Madrid

2025-08-26

Recruiting

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244Healthy

DrugPrevnar 20

Pfizer

Phase 3

6,000

Santiago de Compostela, Esplugues de Llobregat, Pozuelo de Alarcón, Torrejón de Ardoz, Madrid, Antequera, Aravaca, Seville

2025-08-25

Recruiting

Moderate-Intensity Exercise and Pain Sensitization in Breast Cancer Survivors: A Case-Based Study

NCT07128030Exercise Training, Breast Cancer, Pain Management

Universidad Rey Juan Carlos

Not applicable

Madrid

2025-08-23

Recruiting

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

NCT07151040Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC)

One-carbon Therapeutics AB

Phase 1/2

Barcelona, Madrid

2025-08-22

Recruiting

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

DrugsEmpasiprubart·IVIG

argenx

Phase 3

218

Madrid, Sant Andreu de la Barca, Seville

2025-08-22

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT07018700Episodic Migraine

DrugXeomin

Merz Therapeutics GmbH

Phase 3

990

Barcelona, Madrid, Málaga, Seville, Terrassa, Valencia, Vigo, Zaragoza

2025-08-21

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713Chronic Migraine

DrugXeomin

Merz Therapeutics GmbH

Phase 3

780

Barcelona, Madrid, Málaga, Seville, Terrassa, Valencia, Vigo, Zaragoza

2025-08-21

Recruiting

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

NCT06959524Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries

Boston Scientific Corporation

Not applicable

1,616

Madrid, Valencia, Valladolid

2025-08-21

Recruiting

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer

Pfizer

Phase 1

540

Barcelona, Madrid

2025-08-20

Recruiting

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer

DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone

Astellas Pharma Global Development, Inc.

Phase 2

218

Barcelona, Madrid, Santiago de Compostela

2025-08-19

Recruiting

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

NCT07086976Autoimmune Haemolytic Anaemia

DrugRilzabrutinib

Sanofi

Phase 3

Seville, Bizkaia, Barcelona, Majadahonda, Madrid

2025-08-18

Active, closed

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin

Amgen

Phase 3

350

Málaga, Barcelona, Majadahonda, Valencia, Madrid

2025-08-18

By invitation

Impact of Specific Oligomeric Supplementation in Oncologic Patients Undergoing Radiotherapy With Malnutrition or at Risk.

NCT07035132Malnutrition in Elderly, Oncological Patients, Digestive Disorders

Outcomes'10

Observational

132

Alicante, Madrid, Oviedo, Palma de Mallorca

2025-08-15

Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

150

Alcorcón, Madrid, Burgos, Salamanca, Seville

2025-08-14

Recruiting

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT07059000Chronic Primary Immune Thrombocytopenia (ITP)

DrugKedrion IVIG

Kedrion S.p.A.

Phase 3

Burgos, A Coruña, Madrid

2025-08-13

Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232Advanced Solid Tumor

DrugsBNT326·Paroxetine·Itraconazole·Pumitamig

BioNTech SE

Phase 1/2

1,438

Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Valencia

2025-08-12

Recruiting

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

NCT06975865Sickle Cell Disease

DrugRilzabrutinib

Sanofi

Phase 3

192

Madrid

2025-08-12

Recruiting

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease

Abcentra

Phase 2

240

Córdoba, Madrid, El Palmar, Seville

2025-08-11

Recruiting

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

NCT06979596Malignant Neoplasm

DrugsOpevesostat·Tamoxifen·Exemestane·Letrozole

Merck Sharp & Dohme LLC

Phase 2

250

L'Hospitalet de Llobregat, A Coruña, Madrid

2025-08-11

Recruiting

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

NCT07099898Neoplasms, Lung

DrugsRis-Rez·Risvutatug rezetecan·Topotecan

GlaxoSmithKline

Phase 3

420

Barcelona, L'Hospitalet de Llobrega, Las Palmas de Gran Canar, Madrid, Santander

2025-08-11

Recruiting

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

NCT07172516Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

400

Madrid, Palma de Mallorca, Pontevedra

2025-08-08

Recruiting

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

NCT06892054Pancreatic Adenocarcinoma

DrugSotorasib

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Phase 1

Zaragoza, Barcelona, Santander, Córdoba, Donostia / San Sebastian, Madrid, Málaga, Pamplona

2025-08-08

Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

NCT07098338Non-Small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

278

A Coruña, Madrid, Manresa, Málaga, Santander, Valencia

2025-08-07

Recruiting

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

NCT07007793Primary Hyperaldosteronism

DrugBaxdrostat

AstraZeneca

Phase 3

250

Barcelona, Madrid, Seville

2025-08-07

Recruiting

Evaluation of Safety and Effectiveness of an IOL With a Virtual Aperture Optic

NCT05955846Intraocular Lens, Cataract, Presbyopia

Z Optics, Inc.

Not applicable

Alicante, Ceuta, Córdoba, Madrid, Palma de Mallorca

2025-08-07

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Santiago de Compostela, Seville, Esplugues de Llobregat, Bizkaia, Barcelona, Alcalá de Henares, Madrid, Pamplona

2025-08-06

Recruiting

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms

Eli Lilly and Company

Phase 1

421

Barcelona, Madrid

2025-08-06

Active, closed

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

NCT07092865Respiratory Syncytial Virus Infections

GlaxoSmithKline

Phase 2

168

A Coruña, Barcelona, Córdoba, Madrid, Santander

2025-08-06

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Barcelona, Girona, Madrid, Majadahonda, Málaga, Oviedo, Sabadell, Santander

2025-08-06

Recruiting

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT06774131Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma

UroGen Pharma Ltd.

Phase 3

Barcelona, A Coruña, Madrid, Cadiz, Córdoba, Murcia, Seville, Valencia

2025-08-06

Recruiting

Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)

NCT06709339Polypoidal Choroidal Vasculopathy

DrugsVabysmo·Faricimab

Association for Innovation and Biomedical Research on Light and Image

Phase 4

120

Barcelona, Madrid, Oviedo, Valencia

2025-08-06

Active, closed

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

NCT07142811Viral Hepatitis

DrugsTobevibart·Elebsiran·Bulevirtide

Vir Biotechnology, Inc.

Phase 2

100

Barcelona, Madrid, Valencia

2025-08-05

Recruiting

Comparison of Fluoroscopy-only vs. Electroanatomic Mapping Strategies for Pulmonary Vein Isolation With Balloon-based Pulsed-field Ablation

NCT07118046Atrial Fibrillation

Daniel Rodríguez Muñoz

Not applicable

Madrid

2025-08-05

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102Non-Squamous Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin

AbbVie

Phase 2/3

854

Barcelona, Madrid, Valencia

2025-08-03

Recruiting

Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury

NCT06677229Acute Spinal Cord Injury (SCI)

Technophage, SA

Phase 1/2

Córdoba, Madrid

2025-08-01

Recruiting

A Study of Dotinurad Versus Allopurinol in Participants With Gout

NCT07089875Gout

DrugsDotinurad·Allopurinol

Crystalys Therapeutics

Phase 3

500

A Coruña, Santiago de Compostela, Alcobendas, Madrid, Seville, Barcelona

2025-08-01

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Badalona, Barcelona, Córdoba, El Palmar (Murcia), L'Hospitalet de Llobregat, Madrid, Málaga, Oviedo

2025-08-01

By invitation

International Prospective Multicentre Study That Evaluate the Sentinel Lymph Node Detection Rate in Patients With First Local Recurrent Scamous Cell Carcinoma of the Vulva.

NCT07023601Recurent Vulvar Carcinoma

Hospital Universitario La Paz

Not applicable

100

Madrid

2025-08-01

Recruiting

Multitarget Pulse Field Ablation Guided by Endocardial and Non-invasive Atrial Driver Mapping (PFA+ADM) Pilot Study. Development of an Ablation Strategy to Improve the Efficacy of Long Standing Atrial Fibrillation Ablation in Patients With High Comorbidity Burden or Heart Failure

NCT07118488Persistent Atrial Fibrillation Longstanding

Fundacion para la Innovacion en Biomedicina (FIBMED)

Not applicable

Madrid

2025-08

Not yet open

Quality of Life and Sleep in Patients With Temporomandibular Disorders

NCT07056725Temporomandibular Disorders (TMDs)

University of Jaén

Not applicable

Madrid

2025-08

Recruiting

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors

DrugsPanitumumab·Pembrolizumab

Amgen

Phase 1

434

Barcelona, Madrid

2025-07-31

Recruiting

Capella Scientia Development Study

NCT06987474Cataract

Alcon Research

Observational

400

Madrid

2025-07-30

Active, closed

A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation

NCT06808217Atrial Fibrillation, Pulsed Field Ablation, FARAPULSE

Boston Scientific Corporation

Observational

550

Bilbao, Madrid

2025-07-30

Recruiting

Harmony TPV EMEA PMS

NCT06906926Severe Pulmonary Valve Regurgitation

Medtronic Cardiovascular

Not applicable

Madrid

2025-07-30

Active, closed

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

NCT07128550Viral Hepatitis

DrugsTobevibart·Elebsiran·Bulevirtide

Vir Biotechnology, Inc.

Phase 3

150

Barcelona, Madrid, Santander

2025-07-30

Recruiting

A Study With CIT-013 in RA Patients

NCT06567470Rheumatoid Arthritis

DrugsCIT-013 medium·CIT-013

Citryll BV

Phase 2

A Coruña, Barcelona, Madrid, Santander, Santiago de Compostela

2025-07-29

Active, closed

A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

NCT06878365Type 1 Interferonopathies

Boehringer Ingelheim

Phase 1

Barcelona, Madrid, Seville

2025-07-29

Active, closed

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

NCT07038369Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms

DrugATV-1601

Atavistik Bio, Inc

Phase 1

134

Madrid

2025-07-29

Recruiting

EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)

NCT07047703Axial Spondyloarthritis (AxSpA)

Grey Wolf Therapeutics

Phase 1/2

140

Madrid, Córdoba, Sabadell

2025-07-28

Recruiting

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

NCT07080905Hemophilia B

CSL Behring

Phase 3

Barcelona, Madrid

2025-07-28

Recruiting

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06911502Follicular Lymphoma

DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine

Celgene

Phase 3

400

Sabadell, Santander, Madrid, Valencia, Granada

2025-07-28

Recruiting

A Study of LY4175408 in Participants With Advanced Cancer

NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis

DrugsCisplatin·Carboplatin·Pembrolizumab

Eli Lilly and Company

Phase 1

240

Barcelona, Madrid

2025-07-28

Recruiting

Pilot Study to Evaluate the Feasibility, Adherence and Acceptance of the MiDiálisis Platform for Patients on PD

NCT07326085Peritoneal Dialysis (PD)

Aida Frías González

Not applicable

Madrid

2025-07-27

Recruiting

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer

DrugPanitumumab

Astellas Pharma Inc

Phase 1

364

Barcelona, Madrid

2025-07-25

Recruiting

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

NCT07010159Pericarditis, Pericarditis Acute, Recurrent Pericarditis

DrugKPL-387

Kiniksa Pharmaceuticals International, plc

Phase 2/3

325

Barcelona, Madrid, Murcia, Valencia

2025-07-25

Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634Breast Cancer

DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole

Celcuity Inc

Phase 3

1,180

A Coruña, Badajoz, Barcelona, Cáceres, El Palmar, L'Hospitalet de Llobregat, Lleida, Madrid

2025-07-24

Recruiting

Left Bundle Branch Area Pacing (LBBAP) PMCF Study

NCT07217392Bradycardia, Right Ventricular Pacing, Heart Failure, Atrial Fibrillation (AF)

Abbott Medical Devices

Not applicable

200

Madrid

2025-07-24

Active, closed

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

NCT07120503Asthma (Diagnosis)

DrugWIN378

Windward Bio

Phase 2

136

Chiclana de la Frontera, Madrid, San Sebastián, Pozuelo de Alarcón, Benalmádena, Málaga, Seville

2025-07-24

Recruiting

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244Acute Ischemic Stroke, Cerebral Stroke

DrugSovateltide

Pharmazz, Inc.

Phase 3

514

Badalona, Barcelona, Albacete, Madrid, El Palmar, Seville, Tarragona, A Coruña

2025-07-24

Recruiting

EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors

NCT07163325Advanced Solid Tumor (Phase 1)

Epics Therapeutics

Phase 1

Barcelona, Madrid, Santiago de Compostela

2025-07-24

Recruiting

Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)

NCT07113223Heart Failure, Cardiovascular Risk Factors

Idoven 1903 S.L.

Not applicable

1,968

Madrid, Santander

2025-07-23

Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsSigvotatug vedotin·Pembrolizumab

Pfizer

Phase 3

714

A Coruña, Elche, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Palma, Madrid, Valencia

2025-07-23

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Badalona, Santander, A Coruña, Barcelona, Madrid, Seville

2025-07-21

Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)

DrugsZanzalintinib·Everolimus

Exelixis

Phase 2/3

440

Barcelona, Madrid, Murcia, Oviedo, Santander, Santiago de Compostela, Seville, Valencia

2025-07-21

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT06976203Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

586

Barcelona, Donostia / San Sebastian, Santander, Pozuelo de Alarcón, Valencia, Madrid

2025-07-21

Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

NCT07049926Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 1/2

140

Madrid, Barcelona

2025-07-20

Recruiting

Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma

NCT07057596Mestastatic Uveal Melanoma

DrugTebentafusp

Grupo Español Multidisciplinar de Melanoma

Phase 2

L'Hospitalet de Llobregat, Madrid, Valencia

2025-07-18

Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

NCT07079631Metastatic Colorectal Cancer

DrugsBNT314·Pumitamig·Bevacizumab

BioNTech SE

Phase 1/2

482

Barcelona, Madrid

2025-07-18

Active, closed

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

NCT06933329Non-Small Cell Lung Cancer

DrugZelenectide pevedotin

BicycleTx Limited

Phase 2

A Coruña, Madrid

2025-07-18

Recruiting

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

NCT06950385Familial Adenomatous Polyposis (FAP)

DrugERapa

Rapamycin Holdings Inc.

Phase 3

168

Barcelona, Inca, Madrid, Valencia

2025-07-18

Recruiting

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

NCT07015697Recurrent or Metastatic Solid Tumors

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 1

Barcelona, Madrid, Seville

2025-07-17

Recruiting

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712Gastroesophageal Adenocarcinoma

DrugsSonesitatug Vedotin·Calcium folinate·Rilvegostomig·Trastuzumab deruxtecan

AstraZeneca

Phase 2

100

Barcelona, Elche, Madrid, Málaga, Ourense, Oviedo, Santander, Valencia

2025-07-17

Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive

DrugsNeladalkib·Alectinib

Nuvalent Inc.

Phase 3

450

A Coruña, Badalona, Barcelona, Girona, Madrid, Málaga, Seville

2025-07-17

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsBevacizumab biosimilar·Calderasib·Mvasi·Erbitux

Merck Sharp & Dohme LLC

Phase 3

477

Badalona, Santander, Las Palmas de Gran Canaria, Oviedo, Barcelona, Madrid, Seville, Valencia

2025-07-16

Recruiting

Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis

NCT06533852Decompensated Cirrhosis

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Phase 3

190

Barcelona, Madrid, Sabadell, Santander

2025-07-16

Recruiting

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis

DrugsUplizna·Inebilizumab·Blinatumomab

Amgen

Phase 2

220

Santander, Barcelona, Madrid

2025-07-16

Recruiting

Implementation of Biomarker-Based Care for mTBI - IMPACTS-BRAINI Study

NCT07311486Mild Traumatic Brain Injury (mTBI)

Hospital Universitario 12 de Octubre

Observational

1,000

Madrid

2025-07-15

Active, closed

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

NCT07105488Atopic Dermatitis (AD)

DrugBFB759

Bluefin Biomedicine, Inc.

Phase 2

225

Alicante, Córdoba, Granollers, Madrid

2025-07-15

Recruiting

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

NCT07107230Advanced Stage Solid Tumors

DrugAmivantamab

Janssen Research & Development, LLC

Phase 1

400

Barcelona, Madrid

2025-07-15

Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827Kidney Disease

DrugMezagitamab

Takeda

Phase 3

347

Badalona, Barakaldo, Pamplona, Barcelona, Madrid, Seville

2025-07-15

Active, closed

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis

DrugsZola-cel·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 2

Barcelona, Esplugues de Llobregat, Donostia / San Sebastian, Madrid, Málaga, Murcia

2025-07-14

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

586

Seville, Sant Cugat del Vallès, Barcelona, Lleida, Pamplona, Madrid

2025-07-14

Recruiting

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

NCT06898515Acute Decompensated Heart Failure

DrugFurosemide

Reprieve Cardiovascular, Inc

Phase 3

400

Barcelona, Madrid, Valencia

2025-07-14

Recruiting

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

NCT07013474COVID-19 Infection

DrugsIbuzatrelvir·Veklury·Remdesivir

Pfizer

Phase 3

300

A Coruña, Córdoba, Badalona, Barcelona, Madrid, Vigo, Alicante, Seville

2025-07-14

Recruiting

A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.

NCT06832722Shock, Cardiogenic

4TEEN4 Pharmaceuticals GmbH

Phase 1/2

A Coruña, Barcelona, Madrid

2025-07-13

Recruiting

Evaluation of a Mobile AI-powered Decision Support System for Insulin Dosing and Glucose Prediction in Type 1 Diabetes: The glUCModel Clinical Trial Protocol

NCT07304778Diabetes (Insulin-requiring, Type 1 or Type 2)

Universidad Complutense de Madrid

Not applicable

Madrid, Toledo

2025-07-11

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

NCT07011732Alzheimer Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

426

Getxo, Elche (alicante), Madrid, Málaga, Pamplona, Salamanca, Seville, Terrassa

2025-07-10

Active, closed

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

NCT07053384HIV Infections

DrugsVH3810109·Fostemsavir

ViiV Healthcare

Phase 1

107

Pozuelo de Alarcón, Barcelona, Córdoba, La Laguna Santa Cruz, Madrid, Palma de Mallorca, Seville, Valencia

2025-07-10

Active, closed

Support C Post-Market Registry

NCT06678490Coronary Arteriosclerosis

OrbusNeich

Observational

282

Barcelona, Lugo, Madrid, Murcia, Seville

2025-07-09

Active, closed

A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

NCT06892288Phosphomannomutase 2 Deficiency, PMM2-CDG

Glycomine, Inc.

Phase 2/3

Esplugues de Llobregat, Madrid

2025-07-09

Recruiting

Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults

NCT06709469Precursor Cell Lymphoblastic Leukemia-Lymphoma

Instituto de Investigación Hospital Universitario La Paz

Phase 1

Madrid

2025-07-08

Active, closed

A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

NCT06975722Ulcerative Colitis

DrugBrivekimig

Sanofi

Phase 2

105

Las Palmas de Gran Canaria, Madrid

2025-07-07

Recruiting

European Venous Registry

NCT06906250Deep Venous Disease of the Lower Limbs

IRCCS San Raffaele

Observational

100

Madrid

2025-07-05

Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT06863272Castration-Resistant Prostatic Cancer, Metastasis

DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide

Merck Sharp & Dohme LLC

Phase 1/2

360

L Hospitalet Del Llobregat, Madrid, Seville

2025-07-03

Active, closed

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT06981078Chronic Obstructive Pulmonary Disease

DrugVerekitug

Upstream Bio Inc.

Phase 2

666

Palma de Mallorca, Torrelavega, Jerez de la Frontera, Cáceres, Granada, Madrid, Pozuelo de Alarcón, Benalmádena

2025-07-02

Not yet open

Clinical Impact of Surgical Wound Morbidity According to the Type of Saphenous Vein Harvesting Technique (Endoscopic vs. Open) in Patients Undergoing Myocardial Revascularization Surgery

NCT07002658CABG-patients, Saphenectomy, Endoscopic Surgery, Wound Complications

Hospital San Carlos, Madrid

Not applicable

356

Madrid

2025-07-01

Not yet open

Safety and Usability of the EXPLORER Exoskeleton in Adults With Neuromuscular Diseases

NCT06894160Neuromuscular Disorders

MarsiBionics

Not applicable

Madrid

2025-07-01

Not yet open

Brimonidine Eye Drops in the Prevention of Myopia Progression

NCT06996236Myopia

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Phase 2

Madrid

2025-07

Recruiting

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

NCT06937931Cervical Dystonia

DrugCorabotase

Ipsen

Phase 2

132

Barcelona, Cadiz, Madrid, Seville

2025-06-30

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

NCT07054515Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis

DrugNizubaglustat

Azafaros B.V.

Phase 3

147

Barcelona, Madrid

2025-06-30

Active, closed

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

NCT07082543Gangliosidoses, GM2, Gangliosidosis, GM1

DrugNizubaglustat

Azafaros B.V.

Phase 3

Barcelona, Madrid

2025-06-30

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

NCT07082725Niemann-Pick Type C Disease

DrugNizubaglustat

Azafaros B.V.

Phase 3

Barcelona, Madrid

2025-06-30

Recruiting

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

NCT06979375Heart Failure

DrugCDR132L

Novo Nordisk A/S

Phase 2

200

Granada, Girona, El Palmar, Barcelona, Denia, Las Palmas de Gran Canaria, Madrid, Majadahonda

2025-06-30

Recruiting

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

NCT06486883Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma

DrugsCDK4/6i·Trastuzumab deruxtecan

MedSIR

Phase 2

200

Barcelona, Cáceres, Girona, Granada, Jaén, Madrid, Majadahonda, Murcia

2025-06-30

Recruiting

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

NCT07045909De Novo Multiple Myeloma, Anitocabtagene Autoleucel

DrugsAnitocabtagene Autoleucel·Isatuximab·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville

2025-06-30

Active, closed

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

NCT06966453Breast Cancer, Breast Neoplasms

DrugDisitamab Vedotin

Pfizer

Phase 1/2

Barcelona, Madrid, Málaga, Valencia, Granada

2025-06-30

Active, closed

Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

NCT06794554Chronic Pulmonary Aspergillosis

Mundipharma Research Limited

Phase 2

Barcelona, Madrid, Martorell, Valencia

2025-06-30

Recruiting

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

NCT07043946Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal

DrugBudoprutug

Climb Bio, Inc.

Phase 1/2

Burgos, Madrid, San Pedro, Valencia

2025-06-30

By invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637Hidradenitis Suppurativa

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

835

Alicante, Badalona, Barcelona, Cadiz, Córdoba, Granada, Granollers, Madrid

2025-06-27

Recruiting

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

NCT06998524Von Willebrand Disease, Type 3

DrugEmicizumab

Hoffmann-La Roche

Phase 3

Madrid, Seville

2025-06-27

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Benalmádena, Granollers, Madrid, Málaga, Mérida, Pozuelo de Alarcón, Santander

2025-06-27

Recruiting

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06995677Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration

DrugTYRA-300

Tyra Biosciences, Inc

Phase 2

Barcelona, Madrid, Santander

2025-06-27

Recruiting

Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis

NCT06315010NSCLC, Brain Metastases, ROS1 Gene Rearrangement

DrugRepotrectinib

MedSIR

Phase 2

Elche, Barcelona, Girona, Madrid, Reus, Alicante, Barakaldo, León

2025-06-27

Recruiting

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

NCT06979362Heart Failure

DrugCDR132L

Novo Nordisk A/S

Phase 2

200

Granada, El Palmar, Barcelona, Las Palmas de Gran Canaria, Madrid, Valencia

2025-06-27

Recruiting

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

NCT07483827C3 Glomerulopathy (C3G), Healthy Adult Participants

eleva GmbH

Phase 1

Barcelona, Madrid, Pamplona, Seville

2025-06-26

Recruiting

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099Crohn's Disease, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

290

Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia

2025-06-26

Recruiting

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

NCT06409936CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia

DrugsAsciminib·Nilotinib

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

160

Barcelona, Bilbao, Girona, Granada, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca

2025-06-26

Recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086Ulcerative Colitis, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

350

Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia

2025-06-26

Active, closed

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919Allergy, Peanut Allergy

DBV Technologies

Phase 3

480

Barcelona, Madrid, Málaga, Santiago de Compostela

2025-06-24

Recruiting

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281Relapsing Multiple Sclerosis

DrugsRemibrutinib·Ocrelizumab

Novartis Pharmaceuticals

Phase 3

400

El Palmar, Valencia, Barcelona, Córdoba, Madrid, Málaga, Seville

2025-06-23

Active, closed

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

NCT06959225Hidradenitis Suppurativa

DrugRuxolitinib

Incyte Corporation

Phase 3

580

Alicante, Badalona, Barcelona, Madrid

2025-06-23

Active, closed

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

NCT07048197Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 1/2

Barcelona, Madrid

2025-06-20

Recruiting

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

NCT06972446Rheumatoid Arthritis

DrugsABBV-8736·ABBV-701·Lutikizumab·Adalimumab

AbbVie

Phase 2

180

Sabadell, Seville, Bilbao, A Coruña, Córdoba, Madrid, Valencia

2025-06-20

Recruiting

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

NCT06959095Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

981

Pozuelo de Alarcón, Marbella, Alzira, Barcelona, Benalmádena, Ferrol, GaldakaoVizcaya, Madrid

2025-06-20

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT07018323Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

210

Madrid

2025-06-19

Recruiting

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257Heart Failure

DrugPF-07328948

Pfizer

Phase 2

620

Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Majadahonda, Madrid, Valencia

2025-06-19

Recruiting

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

NCT06856213Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

DrugsCetuximab·Paclitaxel

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 2

Santiago de Compostela, Badalona, Barcelona, Santander, Granada, A Coruña, Lugo, Madrid

2025-06-18

Active, closed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618Atopic Dermatitis

DrugRuxolitinib

Incyte Corporation

Phase 3

159

Alicante, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Málaga, Santiago de Compostela

2025-06-17

Active, closed

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

NCT07037771Homozygous Familial Hypercholesterolemia

DrugZodasiran

Arrowhead Pharmaceuticals

Phase 3

Barcelona, Córdoba, Madrid

2025-06-17

Recruiting

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

NCT06789913PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation

DrugRLY-2608

Relay Therapeutics, Inc.

Phase 2

277

A Coruña, Barcelona, Madrid

2025-06-13

Recruiting

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

NCT06990880Neoplasms, Prostate

GlaxoSmithKline

Phase 1/2

Badajoz, Barcelona, Madrid, Málaga, Pozuelo de AlarcOn Madr

2025-06-12

Recruiting

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

NCT06878664Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)

DrugsAmino acid·Lanreotide·Octreotide LAR·Lutathera

Grupo Espanol de Tumores Neuroendocrinos

Phase 3

166

Barcelona, L'Hospitalet de Llobregat, Burgos, Granada, Madrid, Oviedo, Seville, Valencia

2025-06-12

Recruiting

Orbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK).

NCT06736665Coronary Arterial Disease (CAD), Coronary Calcification, Coronary Calcified Nodules, Orbital Atherectomy

Spanish Society of Cardiology

Not applicable

Alicante, Lugo, Madrid, Salamanca, Valladolid, Córdoba

2025-06-12

Active, closed

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

NCT06958211Hidradenitis Suppurativa

DrugRuxolitinib

Incyte Corporation

Phase 3

573

Barcelona, Esplugues de Llobregat, Granada, Granollers, Las Palmas de Gran Canaria, Madrid, Manises, Santiago de Compostela

2025-06-12

Recruiting

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

NCT06885034Gastrointestinal Neoplasms

DrugRisvutatug rezetecan

GlaxoSmithKline

Phase 1/2

451

Barcelona, HebrOn, Madrid, Pamplona, Santander, Zaragoza

2025-06-11

Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

630

Barcelona, LHospitalet de Llobregat, Madrid, Marbella, Salamanca, Santander, Seville

2025-06-11

Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568Endometrial Cancer

DrugsDoxorubicin·Docetaxel·Paclitaxel

BioNTech SE

Phase 3

480

Barcelona, Córdoba, Donostia / San Sebastian, Girona, Madrid, Valencia

2025-06-10

Active, closed

PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

NCT06906822Melanoma

DrugsEnfortumab Vedotin·Pembrolizumab

Grupo Español Multidisciplinar de Melanoma

Phase 2

A Coruña, Badalona, Barcelona, Santander, Madrid, Murcia, Seville, Valencia

2025-06-10

Recruiting

Phase I Trial on the Safety of Delayed Infusion of a Naïve T Cell-Depleted Hematopoietic Graft With Memory T Cells in Solid Organ Transplant Recipients

NCT06997471Solid Organ Transplant Complications, Solid Organ Transplant Recipients, Solid Organ Transplant Rejection

Francisco Hernández Oliveros

Phase 1

Madrid

2025-06-10

Recruiting

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06902558Autosomal Dominant Polycystic Kidney Disease

Calico Life Sciences LLC

Phase 2

240

Barcelona, L'Hospitalet de Llobregat, Granada, Madrid, Seville, Valencia

2025-06-09

Active, closed

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

NCT06953583Friedreich Ataxia

DrugsOmaveloxolone·Skyclarys

Biogen

Phase 3

255

Espluges de Llobregat, Madrid

2025-06-09

Recruiting

Developing a Comprehensive Exercise Service for Breast Cancer Process

NCT07380971Breast Cancer

GO fit Lab- Ingesport

Observational

200

Madrid

2025-06-06

Recruiting

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867Myelodysplastic Syndromes

DrugMomelotinib

GlaxoSmithKline

Phase 2

Barcelona, Madrid, Málaga, Ourense, PamplonaNavarra, Salamanca, Valencia

2025-06-05

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

A Coruña, Barcelona, Cáceres, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón

2025-06-04

Recruiting

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125Dravet Syndrome

DrugZorevunersen

Stoke Therapeutics, Inc

Phase 3

170

Madrid, Pamplona

2025-06-04

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

A Coruña, Alicante, Barcelona, Cáceres, Huelva, Madrid, Málaga, Murcia

2025-06-04

Recruiting

Computerized Cognitive Training in Healthy Older Adults and Mild Cognitive Impairment

NCT07598409Mild Cognitive Impairment (MCI), Healthy Aging

Universidad Antonio de Nebrija

Not applicable

156

Madrid

2025-06-04

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Badalona, Barcelona, El Palmar, Esplugues de Llobregat, Granada, Las Palmas de Gran Canaria, Madrid, Málaga

2025-06-04

Recruiting

Comparison Between a Rush and a Conventional Oral Immunotherapy Protocol to Treat Cow's Milk and Hen´s Egg Allergy. CompITO Study

NCT06976775Food Allergy in Children, Milk Allergy, Egg Allergy

DrugConventional

Pablo Rodríguez del Rio

Phase 2/3

Madrid

2025-06-03

Recruiting

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

NCT06958536Crohn's Disease

DrugBrivekimig

Sanofi

Phase 2

Madrid, Seville

2025-06-03

Recruiting

Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus

NCT06701825Kidney Disease, Chronic, Transplant Recipient (Kidney), Immunosuppression

DrugTacrolimus

Instituto de Investigación Hospital Universitario La Paz

Phase 4

114

Madrid

2025-06-02

Recruiting

Success of Endodontic Treatment With Different Obturation Techniques and Sealer Cements

NCT07019298Pulpitis, Periapical Lesions, Periapical Periodontitis, Periapical Pathology

University of Siena

Not applicable

270

Madrid

2025-06-01

Recruiting

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627Venous Leg Ulcer (VLU)

DrugEscharEx

MediWound Ltd

Phase 3

216

Barcelona, Madrid, Pamplona

2025-06-01

Recruiting

Postoperative Pain Evaluation After Obturation With Different Sealers

NCT07018284Periapical Periodontitis, Pulpitis, Necorsis

University of Siena

Not applicable

270

Madrid

2025-06-01

Not yet open

Clinical Trial to Evaluate Three Systems of Osteosynthesis for Fixation of Olecranon Osteotomies in Adults

NCT07014358Olecranon Fracture

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Phase 4

105

Santander, Madrid, Valencia

2025-06

Recruiting

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

DrugOctreotide LAR

Novartis Pharmaceuticals

Phase 3

240

L'Hospitalet de Llobregat, Oviedo, Barcelona, Madrid, Salamanca

2025-05-30

Recruiting

Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With Systemic Sclerosis

NCT07236970Pulmonary Hypertension, Systemic Sclerosis (SSc), Systemic Sclerosis-Associated PAH

Alejandro Cruz Utrilla

Observational

350

Granada, Santander, Barcelona, Madrid

2025-05-30

Recruiting

Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir

NCT06640192HIV-1-infection

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Phase 2

Madrid

2025-05-30

Recruiting

Open, Non-comparative Pilot Study to Evaluate the Safety and Efficacy of Intraovarian Plasma Rich in Growth Factors (PRGF) in Patients With Low Ovarian Reserve

NCT06975683Low Ovarian Reserve

DrugPlasma Rich in Growth Factors

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Not applicable

Madrid

2025-05-30

Recruiting

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

NCT06887088Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases

DrugsFianlimab·Binimetinib·Encorafenib·Cemiplimab

Grupo Español Multidisciplinar de Melanoma

Phase 2

A Coruña, Barcelona, Burgos, Santander, Cáceres, Donostia / San Sebastian, Madrid, Majadahonda

2025-05-29

Recruiting

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

NCT06961006Malignant Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

160

Barcelona, Madrid

2025-05-29

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers

DrugsMIRV·Mirvetuximab Soravtansine

AbbVie

Phase 2

110

Badalona, Jaén, El Palmar, Pamplona, Seville, Barcelona, Madrid, Valencia

2025-05-28

Recruiting

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

NCT06780098Lung Neoplasm

DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel

Merck Sharp & Dohme LLC

Phase 2

144

L'Hospitalet de Llobregat, Barcelona, Madrid, Seville

2025-05-28

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

3,103

A Coruña, Barcelona, Córdoba, Madrid, Santiago(A Coruña), Seville

2025-05-28

Recruiting

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

NCT07039916Generalized Myasthenia Gravis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 3

231

Barcelona, Córdoba, Madrid

2025-05-27

Recruiting

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative

DrugsSPY001·SPY002·SPY003

Spyre Therapeutics, Inc.

Phase 2

645

Santiago de Compostela, Gijón, Lugo, Madrid, Ourense, Seville

2025-05-27

Recruiting

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

NCT06941272Malignant Neoplasm

DrugPatritumab deruxtecan

Merck Sharp & Dohme LLC

Phase 1/2

Esplugues de Llobregat, Barcelona, Madrid

2025-05-26

Recruiting

Intelligent Lung Support in the Intensive Care Unit

NCT06595602Mechanical Ventilation, Intensive Care Medicine

Technische Universität Dresden

Observational

530

Madrid, Sabadell

2025-05-25

Recruiting

Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

NCT05974774Prostate Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

1,600

Barcelona, Madrid, Majadahonda

2025-05-23

Recruiting

Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

NCT06941025Fabry Disease, Pregnancy, Pregnancy Complications

Chiesi Farmaceutici S.p.A.

Observational

Madrid

2025-05-23

Recruiting

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

NCT05815927Oligometastatic Squamous Cell Carcinoma of the Head and Neck

DrugPembrolizumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

200

Badalona, Barakaldo, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga

2025-05-23

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Elche, San Cugat Del Valles Barcelona, Madrid, Navarra, A Coruña, Barcelona, El Palmar, Lleida

2025-05-22

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

L'Hospitalet de Llobregat, Girona, Barcelona, Córdoba, Madrid, Valencia

2025-05-22

Active, closed

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

NCT06843590Idiopathic Hypersomnia

DrugALKS 2680

Alkermes, Inc.

Phase 2

126

Barcelona, Madrid

2025-05-22

Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301Advanced Melanoma

DrugsEIK1001·Keytruda·Pembrolizumab

Eikon Therapeutics

Phase 2/3

740

Santiago de Compostela, Badalona, Barcelona, Santander, Cáceres, Lugo, Girona, Madrid

2025-05-22

Recruiting

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

NCT06865651Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 2

Barcelona, Pamplona, Alicante, Madrid

2025-05-22

Active, closed

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

NCT06966479Severe Asthma

DrugVerekitug

Upstream Bio Inc.

Phase 2

396

Barcelona, Madrid

2025-05-21

Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581Asthma

DrugTilrekimig

Pfizer

Phase 2

252

Santander, Madrid, Pozuelo de Alarcón, Málaga

2025-05-20

Recruiting

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

NCT06935370Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

4,200

Barcelona, Madrid, Sanlúcar de Barrameda, Torrejón de Ardoz, Valencia, Villamartín

2025-05-20

Recruiting

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737Lymphoma

DrugsDuvelisib·Bendamustine·Gemcitabine

SecuraBio

Phase 3

124

Barcelona, Madrid, Salamanca, Seville

2025-05-19

Recruiting

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798Delayed Graft Function, DGF, Kidney Transplant

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

450

Badajoz, Barakaldo, Barcelona, Cadiz, Córdoba, Granada, Madrid, Málaga

2025-05-19

Recruiting

Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme

NCT06696534Screening for Colon Cancer, Survey and Questionnaire

ADVANCED MARKER DISCOVERY S.L.

Not applicable

1,000

Madrid

2025-05-19

Active, closed

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

NCT06898957Small Cell Lung Cancer

DrugsTam-Peli·Tarlatamab·Durvalumab

Amgen

Phase 1

Barcelona, Majadahonda, Madrid

2025-05-16

Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993Atopic Dermatitis

Novartis Pharmaceuticals

Phase 2

224

Badalona, Alicante, Granada, Las Palmas GC, Madrid, Pontevedra

2025-05-16

Active, closed

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

NCT06993610Hidradenitis Suppurativa (HS)

Zura Bio Inc

Phase 2

225

Córdoba, Madrid, Zaragoza

2025-05-16

Recruiting

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867Acute Ischemic Stroke

Corxel Pharmaceuticals

Phase 2/3

740

A Coruña, Albacete, Barcelona, Girona, Madrid, Málaga, Seville, Valencia

2025-05-15

Recruiting

Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine

DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab

AstraZeneca

Phase 2

150

Barcelona, Girona, Las Palmas de Gran Canaria, Lugo, Madrid, Santiago de Compostela

2025-05-15

Active, closed

Study of GS-0151 in Participants With Rheumatoid Arthritis

NCT06902519Rheumatoid Arthritis

Gilead Sciences

Phase 1

A Coruña, Barcelona, Madrid, Sabadell, Seville

2025-05-14

Recruiting

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

NCT07003425Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

350

Santiago de Compostela, Las Palmas de Gran Canaria, Madrid

2025-05-14

Active, closed

RADIQAL Study (Radiation Dose and Image Quality Trial)

NCT06944509Coronary Artery Disease

Philips Clinical & Medical Affairs Global

Not applicable

824

Madrid

2025-05-14

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Santander, Santiago de Compostela, Majadahonda Madrid, Madrid, Barcelona, Córdoba, Lugo, Seville

2025-05-13

Recruiting

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

NCT06780085Carcinoma, Non-Small-Cell Lung

DrugsR-DXd·Ifinatamab Deruxtecan

Merck Sharp & Dohme LLC

Phase 2

L'Hospitalet de Llobregat, Madrid

2025-05-13

Recruiting

Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution

NCT06941012Parkinson Disease (PD)

Casa di Cura IGEA

Observational

1,200

Madrid

2025-05-12

Active, closed

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280Type 1 Diabetes, Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

465

Badajoz, Badalona, Barcelona, Madrid, Seville

2025-05-12

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

130

Palma, Santander, Barcelona, Madrid, Seville, Toledo

2025-05-12

Recruiting

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819891Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

425

Alcorcón, Majadahonda, Madrid, Zaragoza

2025-05-12

Recruiting

FB-CT2 Includes Two Prospective, Multi-centre Studies With a Medical Device in Hospital Settings: a Randomized, Dual-arm, Open-label Pilot Study in Spain, Followed by a Single-arm, Non-randomized, Open-label International Pivotal Study

NCT06968364Threatened Preterm Labor

Ultrasound-Innovation Medtech, S.L.

Not applicable

457

A Coruña, Barcelona, Bilbao, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Málaga

2025-05-10

Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357Immunoglobulin A Nephropathy (IgAN)

DrugFelzartamab

Biogen

Phase 3

454

Viladecans, Barcelona, A Coruña, Alcorcón, Getafe, Cáceres, Girona, Madrid

2025-05-08

Active, closed

A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors

NCT06932952Solid Tumor

DrugsBYON4228·Pembrolizumab

Byondis B.V.

Phase 1

Madrid

2025-05-07

Recruiting

Safety of HRX215 in Patients After Minor and Major Liver Resection

NCT06638502Liver Resection, Colorectal Carcinoma Liver Metastases

HepaRegeniX GmbH

Phase 1/2

Madrid, Valencia

2025-05-06

Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785Hepatocellular Carcinoma

DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab

AstraZeneca

Phase 3

1,220

Barcelona, Madrid, Santander

2025-05-06

Recruiting

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

NCT06952699Narcolepsy Type 2

DrugTAK-360

Takeda

Phase 2

Madrid

2025-05-06

Recruiting

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285Myelodysplastic Syndromes

DrugElritercept

Takeda

Phase 3

225

Salamanca, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2025-05-06

Active, closed

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

NCT06799247Myasthaenia Gravis

Cartesian Therapeutics

Phase 3

128

Barcelona, Madrid

2025-05-06

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)

DrugsCetuximab·Docetaxel

Revolution Medicines, Inc.

Phase 3

590

A Coruña, Barcelona, Fuencarral-El Pardo, Madrid

2025-05-06

Recruiting

VitaFlow LIBERTY Europe

NCT06535659Aortic Valve Stenosis

Shanghai MicroPort CardioFlow Medtech Co., Ltd.

Observational

222

A Coruña, Madrid, Valladolid

2025-05-06

Recruiting

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

NCT06652438Acute Myeloid Leukemia, Adult

DrugRevumenib

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 3

448

Alicante, Barcelona, Girona, Lleida, Madrid, Palma de Mallorca, Tarragona, Valencia

2025-05-05

Recruiting

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06967805Idiopathic Pulmonary Fibrosis

Mediar Therapeutics

Phase 2

164

Barcelona, Lugo, Madrid, Santander

2025-05-05

Recruiting

PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

NCT06855329Progressive Pulmonary Fibrosis, Interstitial Lung Disease

University of Massachusetts, Worcester

Observational

500

Madrid

2025-05-01

By invitation

Cities for Better Health Childhood Obesity Prevention Initiative

NCT06855563Obesity

Novo Nordisk A/S

Not applicable

36,000

Madrid

2025-04-30

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

NCT06884618Neoplasms

Hoffmann-La Roche

Phase 1

405

Pamplona, Barcelona, Madrid

2025-04-30

Active, closed

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

NCT06883240Von Willebrand Disease, Type 3

DrugsActivated Prothrombin Complex·Recombinant Factor VIIa

Hoffmann-La Roche

Observational

Madrid, Seville

2025-04-29

Recruiting

Skin Type Determination Using Image Artificial Intelligence

NCT07765303Skin Ageing, Skin

Region Skane

Observational

1,500

Madrid

2025-04-28

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

A Coruña, Santiago de Compostela, Barcelona, Hospitalet, Palma, Madrid, Majadahonda, Pontevedra

2025-04-24

Recruiting

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

NCT06820463Metastatic Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Panitumumab·Fluorouracil·Leucovorin

AbbVie

Phase 2

390

Santander, Pamplona, Barcelona, Madrid, Valencia

2025-04-24

Recruiting

Validation Study of the EMILY AI Device in Acute and Chronic Respiratory Failure

NCT06952816Chronic Respiratory Failure, Acute Respiratory Failure

Aether Tech S.L.

Not applicable

Madrid

2025-04-23

Active, closed

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

NCT06928142Sjogren Disease

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2

Santander, Castelló, Madrid, Torrevieja

2025-04-23

Recruiting

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer

DrugPumitamig

BioNTech SE

Phase 1/2

380

Barcelona, Madrid, Pozuelo de Alarcón

2025-04-23

Recruiting

Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders

NCT06450704Major Depressive Disorder, Inflammatory Response

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Not applicable

124

Alcalá de Henares, Majadahonda, Madrid

2025-04-21

Recruiting

Is it Really Necessary Going All Over the Top in Patients With Symptomatic Lumbar Spinal Stenosis?

NCT07026305Lumbar Canal Stenosis, Lumbar Spinal Stenosis, Lumbar Spinal Stenosis (LSS)

Universidad Complutense de Madrid

Not applicable

Madrid

2025-04-21

Recruiting

Optimising TREATment for Severe Gram-Negative Bacterial Infections

NCT07004049Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection

DrugsCeftolozane-tazobactam·Cefiderocol·Fosfomycin·Meropenem-Vaborbactam

National University of Singapore

Phase 4

600

Alicante, Badajoz, Barakaldo, Barcelona, Córdoba, Granada, Madrid, Málaga

2025-04-21

Recruiting

Study To Evaluate The Efficacy And Safety Of A Nutritional Supplement Based On Bergamot, Artichoke And Other Ingredients For Reducing Cholesterol Levels In Patients With Hypercholesterolemia (Metachol+)

NCT07178769Cholesterolemia

Laboratoires Arkopharma

Not applicable

207

Madrid, Cartagena, Mazarrón

2025-04-20

Recruiting

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

Avalyn Pharma Inc.

Phase 2

340

Granada, Barcelona, Santander, Madrid, Málaga

2025-04-17

Recruiting

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06966401Major Depressive Disorder

DrugNBI-1065845

Neurocrine Biosciences

Phase 3

850

Madrid

2025-04-16

Active, closed

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

NCT06814145Hypertension, Pulmonary

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

440

Marbella, Barcelona, Madrid, Seville, Toledo

2025-04-16

Recruiting

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

NCT06843447Ovarian Cancer Recurrent

DrugsMK-2010·R-DXd·Zirabev·Pegylated liposomal doxorubicin

Merck Sharp & Dohme LLC

Phase 1/2

605

L'Hospitalet de Llobregat, Majadhonda, Madrid, Valencia, Barcelona, Málaga

2025-04-15

Active, closed

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226Plaque Psoriasis

DrugsIcotrokinra·Ustekinumab

Janssen Research & Development, LLC

Phase 3

752

Alicante, Barakaldo, Barcelona, Granada, Madrid, Manises, Santiago Compostela, Seville

2025-04-15

Recruiting

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT06795412Advanced Solid Tumors

DrugsPYX-201·Keytruda·Pembrolizumab

Pyxis Oncology, Inc

Phase 1/2

220

Barcelona, Madrid, Valencia

2025-04-15

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

NCT06858813Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer

DrugLenvatinib

AbbVie

Phase 1

232

Madrid

2025-04-14

Recruiting

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer

DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab

Corcept Therapeutics

Phase 2

270

Badalona, Barcelona, Madrid, Valencia

2025-04-11

Recruiting

Safeguarding the Brain of Our Smallest Children-IIIv (SafeBoosC-IIIv)

NCT05907317Hypoxia, Infant, Newborn, Diseases

Copenhagen Trial Unit, Center for Clinical Intervention Research

Phase 3

1,610

Madrid

2025-04-11

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277Carcinoma, Non-Small Cell Lung

DrugsRilvegostomig·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

830

Badajoz, Badalona, Barcelona, Castellon, Granada, Jaén, Lugo, Madrid

2025-04-10

Recruiting

Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

NCT06943469Atopic Dermatitis (AD)

Société des Produits Nestlé (SPN)

Not applicable

400

A Coruña, Almería, Barcelona, Madrid, Málaga, Seville, Tarragona, Zaragoza

2025-04-10

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693Breast Cancer

DrugsCDK4/6i·Inavolisib·Letrozole

Hoffmann-La Roche

Phase 3

450

Elche, L'Hospitalet de Llobregat, Pamplona/iruña, Bilbao, Barcelona, Madrid, Málaga, Seville

2025-04-09

Recruiting

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT05066217Lennox Gastaut Syndrome

DrugClemizole HCl

Epygenix

Phase 3

260

Barcelona, Madrid, Málaga, Pamplona, Seville

2025-04-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

770

Girona, Madrid, Valencia, Barcelona, Córdoba

2025-04-09

Active, closed

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

NCT06822790Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

710

A Coruña, Barcelona, Madrid, Santiago de Compostela, Seville, Valencia, Zaragoza

2025-04-09

Active, closed

Motivational Support for an Autonomous Exercise Program for Healthy Aging

NCT07447453Frailty at Older Adults

Hospital Universitario Getafe

Not applicable

190

Getafe, Madrid

2025-04-08

Recruiting

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)

DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan

Gilead Sciences

Phase 3

695

A Coruña, Barcelona, Girona, Jaén, Las Palmas de Gran Canaria, Madrid, Málaga, Seville

2025-04-04

Recruiting

Clinical Trial With MBK-01, Intestinal Microbiota Capsules, for the Treatment of Patients With Recurrent Diverticulitis

NCT06687382Diverticulitis, Diverticulitis of Sigmoid

Mikrobiomik Healthcare Company S.L.

Phase 2

Madrid

2025-04-03

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

NCT06863961Atopic Dermatitis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

162

Santiago de Compostela, Pamplona, Córdoba, Madrid

2025-04-01

Active, closed

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

NCT06864169Gastrointestinal Cancer

DrugR-DXd

Merck Sharp & Dohme LLC

Phase 2

160

Badalona, Santander, Barcelona, Madrid

2025-04-01

Not yet open

Obesity Prevention in Children and Young People Treated for Acute Lymphoblastic Leukaemia with ALLTogether

NCT06846294Diet Intervention, Physical Activity Intervention, Standard Care Control

University of Exeter

Not applicable

Madrid

2025-04-01

Recruiting

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945Alopecia Areata

DrugsLitfulo·Ritlecitinib

Pfizer

Phase 3

674

Santiago de Compostela, Córdoba, Madrid, Zaragoza

2025-04-01

Recruiting

Preventing Suicide With Digital Phenotyping and Pharmacogenetics-Based Interventions

NCT07422090Suicide Attempt

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Observational

5,000

Madrid

2025-04-01

Not yet open

Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia

NCT06830733Leukemia, Plasma Cell

Fundacion Clinic per a la Recerca Biomédica

Phase 2

Santander, Madrid, Murcia, Pamplona, Salamanca, Barcelona

2025-04

Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450Advanced Solid Tumors Cancer, MSI-H Cancer

Nimbus Wadjet, Inc.

Phase 1/2

134

Barcelona, Madrid

2025-03-31

Recruiting

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06980116Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL)

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Phase 1

Madrid, Pamplona

2025-03-31

Recruiting

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

NCT06731907Non-small Cell Lung Cancer

DrugsPatritumab deruxtecan·Abraxane·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 2

L'Hospitalet de Llobregat, Barcelona, Madrid

2025-03-30

Recruiting

The Pivotal Study of RapidPulseTM Aspiration System

NCT06029491Acute Ischemic Stroke

RapidPulse, Inc

Not applicable

170

Alicante, Badalona, Barcelona, Girona, Madrid

2025-03-27

Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598Carcinoma, Non-Small-Cell Lung

DrugsOlomorasib·Durvalumab·Pembrolizumab

Eli Lilly and Company

Phase 3

700

Badajoz, Barcelona, Hospitalet, Jerez de la Frontera, Las Palmas de Gran Canaria, Madrid, Málaga, Palma

2025-03-27

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

A Coruña, Córdoba, Donostia / San Sebastian, El Palmar, L'Hospitalet de Llobregat, Madrid, Palma de Mallorca, Valencia

2025-03-27

Recruiting

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

NCT06644781Esophageal Squamous Cell Carcinoma

DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel

Daiichi Sankyo

Phase 3

510

Burgos, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Ourense, Oviedo, Pamplona

2025-03-27

Recruiting

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263Asthma

DrugTozorakimab

AstraZeneca

Phase 2

540

Barcelona, Madrid, Málaga, Mérida, Patraix, Santander

2025-03-26

Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT06818643Advanced Solid Tumors, Malignant Neoplasm

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

270

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga

2025-03-25

Recruiting

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

NCT06672523Advanced Solid Tumors With Homozygous MTAP Deletion

DrugNavlimetostat

Bristol-Myers Squibb

Phase 1

Logroño, Madrid

2025-03-24

Recruiting

A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours

NCT06977737Solid Tumor, Adult

Accession Therapeutics Limited

Phase 1/2

Barcelona, Madrid, Rioja

2025-03-21

Recruiting

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

NCT06914128MTAP-deleted Solid Tumors

Bayer

Phase 1/2

450

Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Málaga, Valencia, Pamplona

2025-03-21

Active, closed

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsEfti·Pemetrexed·Keytruda·Paclitaxel

Immutep S.A.S.

Phase 3

756

Badalona, Barcelona, Córdoba, Madrid, Málaga, Oviedo, Sabadell, Seville

2025-03-21

Active, closed

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

NCT06651229Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms

DrugsAzacitadine·Venetoclax

Janssen Research & Development, LLC

Phase 1

Madrid, Pamplona, Seville

2025-03-21

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

565

Granada, Palma, Barcelona, Granollers, Las Palmas GC, Madrid, Pontevedra, Seville

2025-03-20

Active, closed

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823Hereditary Angioedema (HAE)

DrugNavenibart

Astria Therapeutics, Inc.

Phase 3

157

Barcelona, Madrid, Santa Cruz de Tenerife, Seville, Valencia

2025-03-20

Recruiting

NCT06732193Surgical Procedure, Unspecified, Non Small Cell Lung Cancer, Surgery Scheduled, Thoracic Surgery

Carlos Alfredo Fraile Olivero, MD, PhD.

Not applicable

560

Madrid

2025-03-20

Recruiting

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635Breast Neoplasms, Breast Cancer

DrugsPatritumab deruxtecan·Doxorubicin Hydrochloride·Epirubicin·Adriamycin

Merck Sharp & Dohme LLC

Phase 2

372

Badalona, Madrid, Córdoba

2025-03-20

Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

NCT06819007Ovarian Cancer

DrugsTrastuzumab deruxtecan·Bevacizumab

Daiichi Sankyo

Phase 3

582

A Coruña, Barcelona, Córdoba, El Palmar, Madrid, Palma, Pamplona, Planta Baja

2025-03-19

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Barakaldo, Barcelona, Granada, Madrid, Málaga, Palma de Mallorca, Pamplona, Seville

2025-03-18

Active, closed

A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)

NCT06673056Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)

DrugN-Acetyl-L-Leucine

IntraBio Inc

Phase 3

Madrid

2025-03-18

Recruiting

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

NCT06376162Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia

DrugsZiftomenib·Cytarabine·Fludarabine

PedAL BCU, LLC

Phase 1

Barcelona, Madrid

2025-03-18

Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

600

Santander, Galdacao, Madrid, Murcia, Valencia, Valladolid

2025-03-17

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354Triple Negative Breast Neoplasms

DrugsAbraxane·Sacituzumab tirumotecan·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,000

Seville, L'Hospitalet de Llobregat, Madrid, Valencia, Barcelona

2025-03-16

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Sant Joan Despí, Santiago(A Coruña)

2025-03-14

Active, closed

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048Neovascular Age-related Macular Degeneration (nAMD)

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Phase 4

274

Sant Cugat de Valles, Majadahonda, Burjassot, Valencia(España), Madrid, Seville

2025-03-14

Active, closed

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

NCT06833008Advanced Solid Tumor

Ipsen

Phase 1/2

Barcelona, Madrid

2025-03-14

Recruiting

Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

NCT06571149Ischemic Stroke

DrugsAlteplase·Tenecteplase

Insel Gruppe AG, University Hospital Bern

Phase 4

906

A Coruña, Barcelona, Girona, Madrid, Seville, Valladolid, Zaragoza

2025-03-14

Active, closed

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Celgene

Phase 3

960

Córdoba, Barcelona, Sabadell, Barakaldo, Santander, Lugo, Madrid, Majadahonda

2025-03-13

Recruiting

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT06869551Juvenile Psoriatic Arthritis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

Barcelona, Madrid, Valencia

2025-03-13

Recruiting

Video Classification of Intubation in Spain (VCI) (Pediatrics)

NCT06881576Difficult Intubation

Clinica Universidad de Navarra, Universidad de Navarra

Observational

1,500

Madrid

2025-03-12

Recruiting

Advanced Invasive Diagnosis Strategy for Post-PCI Patients With Stable Coronary Syndromes Undergoing Coronary Angiography

NCT07638137Angina (Stable), Percutaneous Coronary Intervention (PCI), INOCA (Ischemia With Non Obstructive Coronary Artery Disease), Chronic Coronary Syndrome

Fundacion Investigacion Interhospitalaria Cardiovascular

Observational

246

Leganés, Madrid, Valencia

2025-03-12

Recruiting

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

NCT06788756Acute Myeloid Leukaemia (AML)

DrugCytarabine

Moleculin Biotech, Inc.

Phase 2/3

312

Barcelona, Oviedo, Madrid, Valencia

2025-03-12

Recruiting

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695Metastatic Colorectal Cancer

DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab

AstraZeneca

Phase 2

Barcelona, Madrid, Málaga, Pamplona, Santander, Valencia

2025-03-12

Recruiting

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466Menstrual Migraine

DrugRimegepant

Pfizer

Phase 3

723

Barcelona, Santander, Chiclana de la Frontera, Madrid, Seville, Valladolid, Zaragoza

2025-03-11

Recruiting

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT06668181Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

Esplugues de Llobregat, Madrid, Valencia

2025-03-11

Recruiting

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

DrugIntismeran autogene

Merck Sharp & Dohme LLC

Phase 2

308

Sabadell, Las Palmas de Gran Canaria, Madrid, Seville

2025-03-11

Recruiting

177Lu-DOTATATE for Recurrent Meningioma

NCT06326190Recurrent Meningioma

DrugsLuTate·Lutathera

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

136

Barcelona, Madrid

2025-03-10

Recruiting

Alleviant ALLAY-HFrEF Study

NCT06812533Heart Failure

Alleviant Medical, Inc.

Not applicable

350

A Coruña, Barcelona, Madrid, Salamanca, Valencia

2025-03-10

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

NCT06671496Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

600

Vitoria-Gasteiz, Santander, Alcobendas, Madrid, Santa Cruz de Tenerife, Seville

2025-03-10

Active, closed

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

NCT06521567Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)

DrugsCobolimab·Dostarlimab

GlaxoSmithKline

Phase 1/2

Barcelona, Madrid, Valencia

2025-03-06

Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 3

300

Barcelona, Madrid, Majadahonda

2025-03-05

Active, closed

An Ophthalmic Safety Study in Patients With Breast Cancer

NCT06767462Ophthalmic Safety in Patients With Breast Cancer

AstraZeneca

Observational

160

Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Leganés, Madrid, Majadahonda, Salamanca

2025-03-05

Recruiting

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

NCT06842355Achondroplasia

DrugTYRA-300

Tyra Biosciences, Inc

Phase 2

Vitoria-Gasteiz, Madrid

2025-03-04

Recruiting

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

NCT06796907Tumours, Gynecological

DrugsMo-Rez·Dostarlimab·Bevacizumab

GlaxoSmithKline

Phase 1/2

305

A Coruña, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2025-03-04

Active, closed

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

NCT06840483Breast Cancer

DrugZelenectide pevedotin

BicycleTx Limited

Phase 2

Barcelona, Madrid

2025-03-03

Recruiting

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

NCT06841055Non-small Cell Lung Cancer

DrugsPumitamig·Docetaxel

BioNTech SE

Phase 2

Barcelona, Madrid, Seville, Valencia

2025-03-03

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Badalona, Barcelona, Madrid, Ourense, Santander, Seville, Valencia

2025-03-01

Active, closed

Efficacy and Usability of the EXPLORER Exoskeleton in Children With Neurodevelopmental Disorders in Natural Environments

NCT06765070Neuromuscular Disorders, Neurodevelopmental Disorders

MarsiBionics

Not applicable

Alcorcón, Madrid

2025-03-01

Recruiting

Double-blind Pilot Study on the Effect of Anionic Exposome Enrichment (Biow) on Recovery and Sleep Quality in Postoperative Patients

NCT06968000Inflammatory Response After Surgery, Postoperative Recovery

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Phase 1/2

150

Madrid

2025-03-01

Active, closed

Exercise and Physical Activity in Children With Pediatric Acquired Brain Injury

NCT06804486Acquired Brain Injury

Universidade da Coruña

Not applicable

Madrid

2025-03-01

Recruiting

BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe

NCT06856902Cardiovascular Diseases, Endocrinology, Inmunology, Neurology

Technical University of Madrid

Not applicable

3,100

Madrid

2025-03-01

Recruiting

Utility of ROTEM® for Risk Stratification of Post-Invasive Procedure Hemorrhage in Patients With Cirrhosis (CIR-ROTEM)

NCT06908785Cirrhosis, Liver

Instituto de Investigación Marqués de Valdecilla

Observational

330

Santander, Alicante, Barcelona, Bilbao, Burgos, Madrid, Oviedo, Toledo

2025-03-01

By invitation

Relationship Between Eating Patterns, Body Composition and the Detection of Fatty Liver in Children and Adolescents With Trisomy 21: LiverTy Project

NCT06888570Obesity Prevention, Pediatric Obesity, Trisomy 21, Down Syndrome (Trisomy 21)

IMDEA Food

Observational

Madrid

2025-03-01

Recruiting

Efficacy of Direct Selective Laser Trabeculoplasty in Clinical Practice in Patients with Glaucoma

NCT06808633Glaucoma

Clínica Rementería

Observational

Madrid

2025-03-01

Not yet open

Implementation of the International Classification of Functioning, Disability and Health Model in Paediatric Cochlear Implant Recipients

NCT06841900Cochlear Impant Children

University Hospital, Antwerp

Observational

120

Madrid

2025-03

Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

600

Alcorcón, Alicante, Badalona, Barcelona, Córdoba, Granada, Las Palmas de Gran Canaria, Madrid

2025-02-28

Recruiting

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

NCT06764316Hepatocellular Carcinoma

Bayer

Phase 1

148

Barcelona, Madrid, Pamplona

2025-02-28

Recruiting

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

DrugsMomelotinib·Reblozyl·Luspatercept

GlaxoSmithKline

Phase 2

Badalona, Barcelona, Las Palmas, Madrid, Málaga, Valencia

2025-02-28

Active, closed

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

NCT06717126Uveal Melanoma, Ocular Melanoma

DrugRoginolisib

iOnctura

Phase 2

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2025-02-27

Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

NCT06780137Small Cell Lung Cancer

DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab

Merck Sharp & Dohme LLC

Phase 1/2

327

Eixample, L'Hospitalet de Llobregat, Madrid, Barcelona, Málaga

2025-02-27

Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

NCT06767514Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

780

Barakaldo, Santander, Badajoz, Las Palmas, Madrid, Sevilla, Marbella, Seville

2025-02-27

Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

171

Alcorcón, Madrid, Salamanca, Seville

2025-02-27

Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer

DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

726

Badalona, Barcelona, Córdoba, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia

2025-02-27

Recruiting

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

NCT06823167Solid Malignancies, Hematologic Malignancies

Immunome, Inc.

Phase 1

190

Madrid

2025-02-26

Active, closed

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

NCT06745323Small Cell Lung Cancer (SCLC)

DrugTarlatamab

Amgen

Phase 2

252

Las Palmas de Gran Canaria, Barcelona, A Coruña, Madrid

2025-02-26

Recruiting

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

NCT06747949Sjögren's Syndrome

DrugDazodalibep

Amgen

Phase 3

844

Santa Coloma de Gramenet, Córdoba, Bilbao, Madrid, Seville

2025-02-25

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276Extensive-Stage Small Cell Lung Cancer

DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin

Bristol-Myers Squibb

Phase 3

530

Santiago de Compostela, Barcelona, Jaén, Madrid, Majadahonda, Valencia, Seville

2025-02-25

Active, closed

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

NCT06617793Relapsing Multiple Sclerosis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 1/2

Barcelona, Córdoba, Madrid, Valencia

2025-02-24

Active, closed

Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI

NCT06811805AKI - Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury

CardioRenal Systems, Inc.

Not applicable

300

Barcelona, Madrid

2025-02-23

Active, closed

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

552

A Coruña, Barcelona, Córdoba, Madrid, Málaga, Sabadell, Santander, Seville

2025-02-21

Recruiting

A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patients Undergoing Debulking Surgery With Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.

NCT07229040Debulking Surgery for Ovarian Cancer, Acute Kidney Injury

Hospital General Universitario Gregorio Marañon

Phase 2

Madrid

2025-02-21

By invitation

Evaluation of the Efficacy of Transcranial Direct Current Stimulation in Reducing Fatigue and Improving Quality of Life in Patients With Multiple Sclerosis: A Randomized Clinical Trial

NCT06873464Multiple Sclerosis, MS

European University of Madrid

Not applicable

Madrid

2025-02-20

Active, closed

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

Badalona, Pamplona, Burjassot, Madrid, Málaga

2025-02-19

By invitation

Effectiveness of a Session of Analgesic Electrostimulation (Invasive and Non-invasive) Applied to the Quadriceps Muscle in Patients After Knee Surgery.

NCT06910150Anterior Cruciate Ligament Reconstruction Rehabilitation

Universidad de Murcia

Not applicable

Madrid

2025-02-18

Recruiting

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

NCT06567782Neoplasms, Colon

DrugsCapeox·Dostarlimab

GlaxoSmithKline

Phase 2

120

Barcelona, Madrid, Oviedo, Valencia

2025-02-18

Recruiting

A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections

NCT06828848Gram Negative Infections

DrugMeropenem

Menarini Group

Phase 2

Barcelona, Cadiz, Girona, Madrid, Málaga, Santiago de Compostela

2025-02-18

Recruiting

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions

NCT07091682Coronary Artery Disease, Atherosclerosis of Coronary Artery, Myocardial Ischemia, Ischemic Heart Disease

Biotronik AG

Not applicable

100

Barcelona, Madrid, Valladolid

2025-02-18

Recruiting

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

NCT06697197Advanced Solid Tumors

DrugsNivolumab and rHuPH20·Opdualag·Bevacizumab

Bristol-Myers Squibb

Phase 1/2

413

Barcelona, Pamplona, Madrid

2025-02-17

Active, closed

Cardiometabolic Properties of Omega-3 Functionalized With Hydroxytyrosol

NCT06992323Hypertriglyceridemia, Normal

National Research Council, Spain

Not applicable

Madrid

2025-02-17

Recruiting

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268Sickle Cell Disease

DrugEtavopivat

Novo Nordisk A/S

Phase 3

510

Barcelona, Madrid, Seville

2025-02-17

Recruiting

Accuracy of Static Guided Implant Surgery: 3D-printed vs Milled Surgical Guides

NCT06819995Dental Implant, Guided Surgery Accuracy

Universidad Complutense de Madrid

Not applicable

Madrid

2025-02-15

Recruiting

Exercise-Induced Hypoalgesia Differences Between Upper and Lower Limbs Resistance Training Interventions

NCT06765486Local Hypoalgesia, Distal Hypoalgesia, Resistance Training, Pressure Pain Thresholds

Centro Universitario La Salle

Not applicable

Madrid

2025-02-15

Recruiting

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819Advanced Solid Tumors, HER2 Mutation

DrugSevabertinib

Bayer

Phase 2

111

L'Hospitalet de Llobregat, Barcelona, Madrid

2025-02-13

Recruiting

The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2

NCT06523400Myotonic Dystrophy

DrugMexiletine

Lupin Ltd.

Phase 3

176

Madrid

2025-02-13

Recruiting

Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants

NCT06823466Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF), Outcome Assessment

University of L'Aquila

Observational

200

Madrid, Valladolid

2025-02-12

Recruiting

Colchicine in Chronic Kidney Disease Patients

NCT06998862Chronic Kidney Disease, Cardiovascular Events

Hospital General Universitario Gregorio Marañon

Phase 3

744

Madrid

2025-02-12

By invitation

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

NCT06908226Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

324

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga, Valencia

2025-02-12

By invitation

A Comprehensive Group Intervention for Psychosocial Personnel at Risk of Stress and Moral Injury

NCT07140263Moral Injury, TEPT

Universidad Complutense de Madrid

Not applicable

Madrid

2025-02-10

Active, closed

Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06806293Menstrual Migraine (MM)

DrugAtogepant

AbbVie

Phase 3

468

Barcelona, Madrid, Valladolid

2025-02-10

Active, closed

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

NCT06748053Asthma

DrugGSK5784283

GlaxoSmithKline

Phase 2

307

Alcorcon Madrid, Barcelona, Benalmádena, Jerez de la Frontera, Madrid, Málaga, Santander, Seville

2025-02-10

Active, closed

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236Platinum-resistant Ovarian Cancer

DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine

Genmab

Phase 3

584

A Coruña, Donostia / San Sebastian, El Palmar, Madrid, Seville, Valencia, Zaragoza

2025-02-07

Recruiting

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

NCT06812078Idiopathic Hypersomnia

DrugTAK-360

Takeda

Phase 2

Vitoria-Gasteiz, Madrid

2025-02-07

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/madrid?page=2

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,046 of those studies with a site in Madrid.

How many clinical trials are recruiting in Madrid?

1,554 of the 3,046 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 117 have not yet opened recruitment, 1,309 are active but closed to new participants, and 66 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.